艾弗梅克在小鼠中减弱了尼古丁诱导的奖励类行为
Mustafa Enes Demirel1, Abdurrahman Ekici2, Oruç Yunusoğlu3
1Department of Emergency Medicine, Bolu Abant Izzet Baysal University, Faculty of Medicine, Bolu, Türkiye.
Biomolecules & biomedicine
|September 26, 2025
概括
抗寄生虫药物伊弗梅克丁在治疗尼古丁成方面表现有前途,通过减少小鼠的依赖性发展和复发. 它可能为尼古丁成提供新的治疗途径.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 成研究 研究成研究
背景情况:
- 尼古丁成是一个主要的公共卫生问题,治疗选择有限.
- 艾弗迈克丁已知的神经递质系统调节表明了成治疗的潜力.
- 现有的尼古丁依赖治疗方法的有效性有限,需要新的方法.
研究的目的:
- 在小鼠模型中调查ivermectin在减轻尼古丁依赖方面的有效性.
- 评估ivermectin对尼古丁诱导的有条件位置偏好 (CPP) 的获得,灭绝和恢复的影响.
主要方法:
- 在获取阶段,小鼠接受了ivermectin (1和5 mg/kg) 和尼古丁 (0.5 mg/kg) 的治疗.
- 有条件的位置偏好 (CPP) 测试被用来建模尼古丁依赖.
- 在灭绝期后,使用尼古丁的原始剂量评估了伊弗梅克丁对尼古丁诱导的CPP恢复的影响.
主要成果:
- 甲 (1和5毫克/公斤) 显著降低了尼古丁依赖的获得.
- 较高剂量的ivermectin (5 mg/kg) 促进了尼古丁诱导的CPP的灭绝.
- 伊弗梅克丁 (5毫克/千克) 减轻了尼古丁诱导的CPP的恢复.
- 没有观察到对运动协调或运动活动的显著影响.
结论:
- 艾弗梅克显示出降低尼古丁依赖获得和复发的潜力.
- 艾弗梅克可能有助于消除尼古丁诱导的行为.
- 这些发现表明,ivermectin作为尼古丁成治疗的潜在治疗剂.
更多相关视频
05:15Author Spotlight: Accessible M&M-Based Mouse Model for Investigating Binge Eating Disorder - Insights into Eating Behaviors, Anxiety, and Neural Mechanisms
Published on: January 10, 2025
1.6K
10:04Local Application of Drugs to Study Nicotinic Acetylcholine Receptor Function in Mouse Brain Slices
Published on: October 29, 2012
19.8K
相关概念视频
01:27CNS Depressants: Alcohol and Nicotine
1.0K
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
1.0K
01:23Drugs Acting on Autonomic Ganglia: Stimulants
2.0K
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
2.0K